Systemic Therapy for Hereditary Breast Cancers

被引：2
|
作者：
Harvey-Jones, Elizabeth J. [1 ]
Lord, Christopher J. [2 ,3 ]
Tutt, Andrew N. J. [1 ,2 ,4 ]
机构：
[1] Breast Canc Now Res Unit, Guys Hosp Canc Ctr, London SE19RT, England
[2] Kings Coll London, City London Canc Res UK Ctr, London SE19RT, England
[3] CRUK Gene Funct Lab, Inst Canc Res, London SW36JB, England
[4] Breast Canc Now Toby Robins Breast Canc Res Ctr, Inst Canc Res, London SW36JB, England
来源：
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2023年 / 37卷 / 01期
关键词：
Hereditary breast cancer; Chemotherapy; PARPi; Drug resistance; Biomarkers; STANDARD NEOADJUVANT CHEMOTHERAPY; PATHOLOGICAL COMPLETE RESPONSE; RANDOMIZED PHASE-II; CELL-FREE DNA; HOMOLOGOUS RECOMBINATION; POLY(ADP-RIBOSE) POLYMERASE; ADJUVANT CAPECITABINE; INHIBITOR RESISTANCE; REVERSION MUTATIONS; GERMLINE MUTATIONS;
D O I：
10.1016/j.hoc.2022.08.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Treatment options for patients with hereditary breast cancers have expanded significantly in the past 20 years. These include a new FDA-licensed approach to adjuvant therapy, olaparib, that improves OS in those with gBRCA1/2m. However, resistance to platinum-based chemotherapy and PARPi in this cohort of patients is an issue that requires considerable focus. We have discussed standard approaches to treatment, but have touched on the expanse of pre-clinical and early clinical work being undertaken which will likely shape future treatments in this field of medicine.
引用
收藏
页码：203 / 224
页数：22
相关论文
共 50 条
  • [31] Assessment of SLX4 Mutations in Hereditary Breast Cancers
    Shah, Sohela
    Kim, Yonghwan
    Ostrovnaya, Irina
    Murali, Rajmohan
    Schrader, Kasmintan A.
    Lach, Francis P.
    Sarrel, Kara
    Rau-Murthy, Rohini
    Hansen, Nichole
    Zhang, Liyng
    Kirchhoff, Tomas
    Stadler, Zsofia
    Robson, Mark
    Vijai, Joseph
    Offit, Kenneth
    Smogorzewska, Agata
    PLOS ONE, 2013, 8 (06):
  • [32] Salivary Gland Cancers: Biology and Systemic Therapy
    Goyal, Gaurav
    Mehdi, Syed A.
    Ganti, Apar Kishor
    ONCOLOGY-NEW YORK, 2015, 29 (10): : 773 - 780
  • [33] ELECTRON THERAPY OF INOPERABLE BREAST CANCERS
    MINET, P
    JOURNAL BELGE DE RADIOLOGIE, 1972, 55 (01): : 113 - &
  • [34] Laser therapy for small breast cancers
    Dowlatshahi, K
    Francescatti, DS
    Bloom, KJ
    AMERICAN JOURNAL OF SURGERY, 2002, 184 (04): : 359 - 363
  • [35] Laser therapy for small breast cancers
    Goldstein, NS
    AMERICAN JOURNAL OF SURGERY, 2004, 187 (01): : 149 - 149
  • [36] Breast Conservative Therapy for Multifocal–Multicentric Breast Cancers
    Chaitra Sonthineni
    A. Verma
    Gaurav Agarwal
    World Journal of Surgery, 2017, 41 : 345 - 345
  • [37] Defective DNA repair in hereditary ovarian cancers: Implications for therapy
    Burgess, Brian T.
    Kolesar, Jill M.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2018, 75 (21) : 1697 - 1707
  • [38] Do apoptotic and proliferative markers help predict the response to systemic therapy in locally advanced breast cancers?
    Varghese, L
    McIntosh, A
    Presthus, J
    Forster, C
    Zhang, Y
    Gulbahce, E
    LABORATORY INVESTIGATION, 2006, 86 : 44A - 44A
  • [39] Do apoptotic and proliferative markers help predict the response to systemic therapy in locally advanced breast cancers?
    Varghese, L
    McIntosh, A
    Presthus, J
    Forster, C
    Zhang, Y
    Gulbahce, E
    MODERN PATHOLOGY, 2006, 19 : 44A - 44A
  • [40] Stem cell therapy for hereditary breast cancer
    H. Rassi
    Cytology and Genetics, 2009, 43 : 216 - 222
12345